UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Clinical Studies of Histone Deacetylase Inhibitors

Clinical cancer research, 2009-06, Vol.15 (12), p.3958-3969

2009

Link zum Volltext

Verfügbarkeit prüfen

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Nature communications, 2021-05, Vol.12 (1), p.3236-3236, Article 3236

2021

Link zum Volltext

Verfügbarkeit prüfen

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Blood, 2017-11, Vol.130 (22), p.2392-2400

2017

Link zum Volltext

Verfügbarkeit prüfen

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2197-2203

2012

Link zum Volltext

Verfügbarkeit prüfen

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Blood, 2014-10, Vol.124 (14), p.2190-2195

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

Clinical cancer research, 2019-07, Vol.25 (13), p.3772-3775

2019

Link zum Volltext

Verfügbarkeit prüfen

Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma

Scientific reports, 2018-03, Vol.8 (1), p.4159-14, Article 4159

2018

Link zum Volltext

Verfügbarkeit prüfen

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

Blood, 2011-02, Vol.117 (5), p.1605-1613

2011

Link zum Volltext

Verfügbarkeit prüfen

Infectious complications of bispecific antibody therapy in patients with multiple myeloma

Blood cancer journal (New York), 2023-03, Vol.13 (1), p.34-34, Article 34

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the cost-effectiveness of [ 18 F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients

Cancer imaging, 2023-12, Vol.23 (1), p.119-119, Article 119

2023

Link zum Volltext

Verfügbarkeit prüfen

Myelosuppressive Therapies Significantly Increase Pro‐Inflammatory Cytokines and Directly Cause Bone Loss

Journal of bone and mineral research, 2015-05, Vol.30 (5), p.886-897

2015

Link zum Volltext

Verfügbarkeit prüfen

Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Internal medicine journal, 2018-02, Vol.48 (2), p.210-220

2018

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease

Journal of health economics and outcomes research (Online), 2024, Vol.11 (1), p.23-31

2024

Link zum Volltext

Verfügbarkeit prüfen

KRd: the new KiD in the French myeloma induction class

Blood, 2021-07, Vol.138 (2), p.105-106

2021

Link zum Volltext

Verfügbarkeit prüfen

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling

Frontiers in immunology, 2017-10, Vol.8, p.1247-1247

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

Clinical hematology international, 2023-03, Vol.5 (1), p.43-51

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

Journal of clinical oncology, 2021-11, Vol.39 (32), p.3602-3612

2021

Link zum Volltext

Verfügbarkeit prüfen

Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma

Expert review of hematology, 2020-11, Vol.13 (11), p.1201-1210

2020

Link zum Volltext

Verfügbarkeit prüfen

The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment

Cancers, 2019-07, Vol.11 (7), p.928

2019

Link zum Volltext

Verfügbarkeit prüfen

Alcohol and tobacco use and risk of multiple myeloma: A case‐control study

EJHaem, 2022-02, Vol.3 (1), p.109-120

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition

Molecular cell, 2021-05, Vol.81 (10), p.2183-2200.e13

2021

Link zum Volltext

Verfügbarkeit prüfen

T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments

Nature (London), 2016-10, Vol.538 (7626), p.518-522

2016

Link zum Volltext

Verfügbarkeit prüfen

Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy

Haematologica (Roma), 2024-03, Vol.109 (3), p.787-798

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.031

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(907)
Mit Volltextzugriff
(891)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(69)
Alzheimer's & Dementia
(24)
Bioorganic & Medicinal Chemistry Letters
(18)
Clinical Lymphoma, Myeloma And Leukemia
(15)
Journal Of Clinical Oncology
(14)
Leukemia & Lymphoma
(13)
Haematologica
(12)
Journal Of Medicinal Chemistry
(12)
Plos One
(11)
Internal Medicine Journal
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Clinical Studies of Histone Deacetylase Inhibitors

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Infectious complications of bispecific antibody therapy in patients with multiple myeloma

Evaluating the cost-effectiveness of [ 18 F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients

Myelosuppressive Therapies Significantly Increase Pro‐Inflammatory Cytokines and Directly Cause Bone Loss

Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease

KRd: the new KiD in the French myeloma induction class

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma

The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment

Alcohol and tobacco use and risk of multiple myeloma: A case‐control study

Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition

T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments

Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy

Suchergebnisse filtern